Micronase: Uses, Dosage & Safety Information

Micronase

Micronase

Micronase

Glyburide
Original non-micronised sulfonylurea brand cleared in 1984 and now discontinued, replaced by generics for grown-ups whose blood sugar runs high. Its form cannot be swapped one-for-one with the micronised version, lows can last for many hours, and bosentan is barred.
  • ActiveIngredient: Glyburide
  • DosageForm: Tablet
  • Dosage: 1.25 mg, 2.5 mg, 5 mg
  • Indications: Type 2 diabetes mellitus
  • Manufacturer: Multiple ANDA holders
  • Storage: 20–25°C (68–77°F)
  • Drug Status: Prescription Only

What is Micronase?

Micronase was Pfizer’s brand of non-micronised glyburide, a sulfonylurea first approved in 1984 to lower blood sugar in adults with type 2 diabetes. All strengths are listed as discontinued, and generic glyburide tablets are supplied instead. Non-micronised and micronised glyburide are not bioequivalent, so anyone switching between them needs a new dose rather than a tablet-for-tablet swap. Low blood sugar remains the main risk.1

Micronase brand discontinued; generics available
Micronase tablets (NDA 017498, approved May 1984) are listed as discontinued in all three strengths; generic glyburide tablets remain FDA-approved, and DiaBeta (NDA 017532) remains a prescription brand.2

Approved products and generic therapeutic-equivalence ratings are listed in the FDA Orange Book.3

Glyburide is marketed in two forms: non-micronised tablets, the form Micronase used, and micronised tablets, the form of the discontinued Glynase brand.2

Micronised glyburide labelling reports that a lower-strength micronised tablet gave blood levels that were not bioequivalent to a higher-strength non-micronised tablet.4

The labelling for non-micronised glyburide states that people moving from other glyburide products or other oral diabetes medicines are retitrated.1

Both labellings state that there is no fixed dosage regimen for glyburide, so the dose is adjusted to each person’s blood glucose.4

Glyburide is broken down in the liver, and its metabolites are cleared roughly half in bile and half in urine, so kidney or liver insufficiency can prolong low blood sugar.1

Micronase belongs to the diabetes medicines; glipizide is another sulfonylurea.

How to Take Micronase

Check your tablet type

If your prescription changes between micronised and non-micronised glyburide, expect a dose review rather than an automatic swap.4

With breakfast

Glyburide is usually taken with breakfast or the first main meal.1

Low blood sugar

Shakiness, sweating, hunger and confusion can signal low blood sugar; take fast-acting sugar and recheck.

Bosentan

Make sure every prescriber knows you take glyburide before bosentan is considered.

Colesevelam

Take glyburide at least four hours before colesevelam.

When lows are more likely

Skipped meals, hard or prolonged exercise, more than one diabetes medicine all raise the chance of low blood sugar.

Before driving

Check your blood sugar before driving, especially after any dose change.

Yellow skin or dark urine

Report yellowing of the skin or eyes, dark urine or persistent itching promptly.

Illness or surgery

During fever, infection, injury or surgery, contact your doctor, as temporary insulin may be needed.

Mixing products

Do not combine micronised and non-micronised glyburide tablets; ask your pharmacist which form you have.4

What Are the Side Effects of Micronase?

The older non-micronised glyburide labelling gives rates for only two kinds of reaction; low blood sugar remains the main risk, and other sulfonylurea-class reactions are listed without frequencies.

Glyburide (Micronase): Reactions
FrequencyEffectNotes
Common — 1.8%Nausea, upper-abdominal fullness, heartburnClinical trials; dose-related
Common — 1.5%Allergic skin reactionsClinical trials; often transient
Frequency not stated in labellingHypoglycaemia, which can be prolongedPrecautions
Frequency not stated in labellingCholestatic jaundice and hepatitisRare
Frequency not stated in labellingBlood disorders and haemolytic anaemia in G6PD deficiencySulfonylurea class

Source: 1

Seek immediate medical attention if:
  • Confusion, seizures or loss of consciousness from low blood sugar
  • Yellowing of the skin or eyes, or dark urine
  • Unusual bruising or frequent infections
  • Blistering rash
Clinical details

Gastrointestinal complaints tend to be dose-related and may resolve when the dose is reduced.

What is Micronase Used For?

Glyburide, the ingredient of Micronase, is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes; it is contraindicated in type 1 diabetes and diabetic ketoacidosis.1

After Micronase

Generic non-micronised glyburide tablets come in the same three strengths that Micronase used, and they must be bioequivalent to their reference product.5

Switching between glyburide forms

Because micronised and non-micronised glyburide are not bioequivalent, a move from one form to the other is managed by retitrating the dose and checking blood glucose, not by matching tablet strengths.4

Who needs extra care

Older, debilitated or malnourished people, those with adrenal or pituitary insufficiency, and people with kidney or liver insufficiency are particularly susceptible to low blood sugar, and starting doses are lower for them.1

Illness, surgery and loss of control

Fever, trauma, infection or surgery can temporarily disturb blood sugar control and may require temporary insulin, and some people lose their response to sulfonylureas over time.

Breastfeeding and children

Because of possible low blood sugar in nursing infants, nursing or the drug is usually stopped, and safety and effectiveness in children have not been established.

Bosentan

Glyburide is contraindicated with bosentan because the combination increased liver enzyme elevations.

Interactions Alcohol:

Use with caution
Alcohol makes low blood sugar more likely with sulfonylureas.

Interactions Other Medications:

Use with caution
Bosentan is contraindicated; NSAIDs, salicylates, warfarin, beta-blockers and colesevelam need care.

Special Groups Pregnancy:

Consult your doctor
No adequate studies in pregnant women; use only if clearly needed.

Special Groups Breastfeeding:

Unsafe
Possible low blood sugar in the infant; nursing or the drug is usually stopped.

Special Groups Elderly:

Use with caution
Older adults are particularly susceptible to low blood sugar; dosing is conservative.

Special Groups Children:

Unsafe
Safety and effectiveness in children have not been established.

Effects on Activities Driving:

Use with caution
Low blood sugar can impair driving; check your sugar first.

Effects on Activities Operating Machinery:

Use with caution
Do not operate dangerous machinery if you feel shaky or confused.

Two forms that are not interchangeable

Micronised glyburide is not bioequivalent to the non-micronised form that Micronase used, so pharmacists and prescribers treat a change of form as a new titration.4

Prolonged low blood sugar

Kidney or liver insufficiency can raise glyburide levels and make low blood sugar long-lasting.1

Brand discontinued

Micronase is listed as discontinued, so non-micronised glyburide is dispensed as generics, which must be bioequivalent to their reference product.5

Where it comes from

Glyburide is prescription-only in the US; the FDA’s BeSafeRx guidance lists four signs of a lawful pharmacy website.6

Critical Warnings for Micronase Use

Contraindications

Glyburide is contraindicated with known hypersensitivity, diabetic ketoacidosis, type 1 diabetes and concomitant bosentan.1

Cardiovascular mortality

A special warning based on the UGDP study notes increased cardiovascular mortality with oral glucose-lowering drugs, applied to all sulfonylureas.

Hypoglycaemia

Severe and prolonged low blood sugar can occur, especially with kidney or liver insufficiency, older age, poor food intake or combination therapy.

Switching formulations

Micronised and non-micronised glyburide are not bioequivalent, so a change of form requires retitration and glucose monitoring.

Haemolytic anaemia

People with G6PD deficiency can develop haemolytic anaemia, and a non-sulfonylurea alternative is considered.

See Interactions for the full list of drug combinations.

Dosage

Micronase Products
FormulationActive IngredientsClinical Note
Non-micronised tablets (generic)Glyburide1.25, 2.5, 5 mg
Usual startGlyburide2.5–5 mg daily with breakfast
More sensitive patientsGlyburideStart 1.25 mg daily
MaintenanceGlyburide1.25–20 mg daily, single or divided
Switching to or from micronised glyburideGlyburideRetitrate; not bioequivalent
Kidney or liver insufficiencyGlyburideConservative dosing

Source: 14

Exceeding the dose
Overdose can cause low blood sugar; mild episodes are treated with oral glucose, while hypoglycaemic coma needs concentrated intravenous glucose and close monitoring, because low blood sugar may recur.1

Marketed strengths and their labelers are listed in the FDA National Drug Code Directory.7

What Does Micronase Interact With?

Interactions by Severity
Interacting SubstanceEffect and RiskSeverityDocumentation
BosentanLiver enzyme elevations; contraindicatedMajorExcellent — labelled
NSAIDs, salicylates, sulfonamides, coumarins, beta-blockersIncreased hypoglycaemic effectModerateGood — labelled
ColesevelamReduced absorption; separate by 4 hoursModerateGood — labelled
Thiazides, corticosteroids, thyroid drugsLoss of glucose controlMinorGood — labelled

Source: 1

No. Micronase, Pfizer’s non-micronised glyburide approved in 1984, is listed as discontinued in all strengths, as is the micronised brand Glynase, while DiaBeta remains on the market. Generic non-micronised glyburide tablets come in 1.25, 2.5 and 5 mg. Ask your pharmacist whether your generic is micronised or non-micronised, because the two forms are dosed differently.
Micronised glyburide, the form of Glynase, is not bioequivalent to non-micronised glyburide, the form Micronase used. Because of this, a switch between the two forms is handled by retitrating the dose and monitoring blood glucose. Do not convert tablet strengths yourself, and do not mix the two forms.
Yes. Glyburide can cause severe low blood sugar, and kidney or liver insufficiency can make it prolonged because the drug and its metabolites are cleared through bile and urine. Older, frail or malnourished people and those who skip meals or exercise hard are most at risk. Keep a fast-acting sugar source with you.
Glyburide is contraindicated with bosentan, because the combination increased liver enzyme elevations. Colesevelam reduces glyburide absorption, so glyburide is taken at least four hours earlier. Anti-inflammatory painkillers, salicylates, warfarin-type drugs and beta-blockers can increase its effect, while thiazides, steroids and thyroid medicines can weaken blood sugar control.
Safety and effectiveness of glyburide in children have not been established, so it is used only in adults with type 2 diabetes. It is contraindicated in type 1 diabetes and diabetic ketoacidosis, which need insulin. Because of possible low blood sugar in nursing infants, breastfeeding mothers usually stop either nursing or glyburide after discussing alternatives with their prescriber.

Evidence scope

What we know
  • Micronase was approved in 1984 and is now discontinued.
  • Micronised and non-micronised glyburide are not bioequivalent.
  • Bosentan is contraindicated with glyburide.
  • There is no fixed dosage regimen; doses follow blood glucose.
What remains uncertain
  • How often low blood sugar occurs; the labelling gives no rate.
  • Safety and effectiveness in children.
  • Whether glyburide passes into human milk.

Source: 1

What has been reported to the FDA

Reports to the FDA naming glyburide are summarised on the glyburide page.8

Who was this medicine studied in?

This older generic labelling reports side-effect rates from clinical trials without stating patient numbers.

Who this is and is not appropriate for

Not for type 1 diabetes, diabetic ketoacidosis, hypersensitivity, or use with bosentan.

Adults with type 2 diabetes previously on Micronase or starting non-micronised glyburide.

Where to report and verify

Routing to Official Registries
What you needWhere to go
Report a side effectFDA MedWatch
Pregnancy-specific dataMotherToBaby
Full prescribing informationDailyMed
Verify a pharmacy websiteFDA BeSafeRx · LegitScript

References

  1. FDA label, Glyburide Tablets USP 1.25, 2.5, 5 mg (Avet Pharmaceuticals; ANDA 090937)
    Revised 2025-10 · Accessed 2026-10-24
    Used for: indication, dosing and retitration, contraindications incl. bosentan, precautions, adverse reactions, interactions, overdose.
    dailymed.nlm.nih.gov — glyburide SPL
  2. Drugs@FDA
    Record accessed 2026-10-24
    Used for: application and marketing status.
    accessdata.fda.gov — Drugs@FDA
  3. FDA Orange Book
    Accessed 2026-10-24
    Used for: reference and generic listings.
    accessdata.fda.gov — Orange Book
  4. FDA label, Glyburide (micronized) Tablets (Teva Pharmaceuticals USA; ANDA 074686)
    Revised 2023-01 · Accessed 2026-10-24
    Used for: bioequivalence of micronised versus non-micronised glyburide, retitration when switching, no fixed dosage regimen.
    dailymed.nlm.nih.gov — glyburide micronized SPL
  5. FDA — Generic Drugs: Questions & Answers
    Accessed 2026-10-24
    Used for: requirements for generic equivalence (same active ingredient, strength, bioequivalence).
    fda.gov — Generic Drugs Q&A
  6. FDA BeSafeRx — signs of a safe pharmacy website (flyer)
    Accessed 2026-10-24
    Used for: four signs of a lawful pharmacy website.
    fda.gov — BeSafeRx
  7. FDA National Drug Code Directory
    Directory accessed 2026-10-24
    Used for: marketed products and strengths.
    accessdata.fda.gov — NDC Directory
  8. FDA Adverse Event Reporting System (openFDA)
    Data cut 2026-07-30 · Accessed 2026-10-24
    Used for: report totals and the ten most frequent terms.
    open.fda.gov — drug adverse event API

How this page was sourced

Clinical facts come from current FDA labelling for generic non-micronised glyburide; the bioequivalence point comes from micronised glyburide labelling.

Brand status comes from Drugs@FDA; the report summary is on the glyburide page.

Disclaimer: The information on this site is provided for informational purposes only and is not medical advice. It does not replace professional medical consultation, diagnosis, or treatment. Do not self-medicate based on the information presented on this site. Always consult with a doctor or other qualified healthcare professional before making any decisions about your health.